A recent study compared the effects of empagliflozin and dapagliflozin on all-cause mortality and hospitalization in patients with heart failure (HF) using the TriNetX Research Collaborative Network database. Among 28,075 patients newly started on either drug, 11,077 in each group were matched for demographics and comorbidities. The primary outcome was a composite of all-cause mortality or hospitalization within one year, with secondary outcomes including individual components of the primary outcome, last measured HbA1c, and adverse effects.

The study found that patients treated with empagliflozin had a lower incidence of the primary composite outcome (32.2% vs. 34.8%, HR 0.90) and a lower risk of hospitalization (HR 0.90) compared to those treated with dapagliflozin, though all-cause mortality rates were similar (HR 0.91). HbA1c levels and adverse event rates were also similar between the groups. These results suggest empagliflozin may be more effective in reducing hospitalizations among patients with HF. Further research is needed to directly compare these SGLT2 inhibitors in randomized controlled trials to confirm these findings and examine differences in cardiac remodeling.

Reference: Modzelewski KL, Pipilas A, Bosch NA. Comparative Outcomes of Empagliflozin to Dapagliflozin in Patients With Heart Failure. JAMA Netw Open. 2024 May 1;7(5):e249305. doi: 10.1001/jamanetworkopen.2024.9305. PMID: 38696170; PMCID: PMC11066699.